FDA Drug Label
SAXENDA (liraglutide) injection — Prescribing Information
Novo Nordisk. FDA Drug Label. 2014
Compare
Liraglutide vs Melanotan II
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.
Liraglutide
6 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 100% · Mixed 0% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Appetite
6
Self-reported dose per injection
Median bucket: 2+ mg · Most common: 2+ mg
Reports span 1 to ≥ 2 mg (open-ended top bucket)
1–2 mg
2
2+ mg
4
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
Melanotan II
46 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 97% · Mixed 3% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Libido
142
Mood
141
Appetite
73
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Fatigue
2
Nausea
2
Self-reported dose per injection
Median bucket: 0.4–0.6 mg · Most common: 0.2–0.4 mg
Reports span 0.01–2 mg
0.01–0.025 mg
1
0.05–0.1 mg
1
0.1–0.2 mg
7
0.2–0.4 mg
49
0.4–0.6 mg
23
0.6–1 mg
33
1–2 mg
28
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 94% said they felt similar to their last entry, 6% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 50 days · Based on 32 repeat reporters
Sources (9)
Published sources linked on the Liraglutide and Melanotan II wiki pages.
- Wiki study page →Source
- Wiki study page →Source
FDA Drug Label
VICTOZA (liraglutide) injection — Prescribing Information
Novo Nordisk. FDA Drug Label. 2010
- Wiki study page →Source
PubMed
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER trial)
Marso SP, Daniels GH, Brown-Frandsen K, et al. N Engl J Med. 2016
- Wiki study page →Source
PubMed
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE)
Pi-Sunyer X, Astrup A, Fujioka K, et al. N Engl J Med. 2015
- Wiki study page →Source
PubMed
Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial
Rubino DM, Greenway FL, Khalid U, et al. JAMA. 2022
- Wiki study page →Source
PubMed
Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial
Garvey WT, Birkenfeld AL, Dicker D, et al. Diabetes care. 2020
- Wiki study page →Source
PubMed
Melanotan II and its molecular mechanisms
Dorr RT, Dawson BV, Hadley ME, et al. Life Sci. 2009
- Wiki study page →Source
PubMed
LC-HRMS characterization of the skin pigmentation and sexual enhancers melanotan II and bremelanotide sold on the black market of performance and image enhancing drugs
Mestria S, Odoardi S, Frison G, et al. Drug testing and analysis. 2021
- Wiki study page →Source
PubMed
Melanotan II injection resulting in systemic toxicity and rhabdomyolysis
Nelson ME, Bryant SM, Aks SE. Clinical toxicology (Philadelphia, Pa.). 2012